ADYA provides ad hoc team creation that can effectively convey clients’ value proposition
thanks to the worldwide and multidisciplinary ADYA network.
Our people impart experience of planning and execution of strategic development plans and a track record of successfully executed financial transactions (equity investments in private companies, pre-IPO deals and M&A).
Silvia is CEO and founder of ADYA. With about 25 years’ experience and several Board positions, Silvia combines a profound understanding of corporate finance and private investments with a deep knowledge of drug development and diagnostics & devices R&D processes.
She has been appointed as COO (Chief Operating Officer) at NLS Pharmaceutics (NASDAQ:NLSP) since NLS listing at NASDAQ, where she set up the development team and drove the lead asset through IND approval and a successful Phase II in an high speed and cost containment.
She was former Managing Director at I-Bankers Direct, an equity funding web-platform and Advisor for I-Bankers Securities group, a US investment banking. She formerly served as Investment Director at BSI Healthcapital, a VC firm focused on life sciences and she was responsible for venture investments and for the set-up of clients’ dedicated vehicles in the Merchant division of a Swiss bank (BSI/EGF bank). She had a Board Seat in several US- and EU-based companies bringing a few of them up to an exit.
Senior Director at XoVenture, a global network of entrepreneurs in the Life Sciences and Start-Up Coach for the Swiss government (Innosuisse), Silvia acquired an extensive R&D experience, having served in operational and C-level positions in pharmaceutical companies – preclinical, clinical and business development in NLS (NASDAQ:NLSP), Bracco and Quintiles. She spent her first years as oncology researcher in Academia in Italy and the US.
She possesses a Molecular Biology degree, a Ph.D. in Molecular Oncology and EMBA from SDA Bocconi.
15 years experience; intelligent global product development and regulatory affairs consultancy, Director at Clinical Network Services.
30 years experience pre-clinical pharma tox and CMC expert for drugs, cell therapies , food ingredient and medical devices.
30 years experience; M&A, strategy, global channels; software, big data analytics, cybersecurity, diagnostics for women’s health; co-founder of Nasdaq listed bank.
One of the most experienced C-level professional with unique expertise in the development of Orphan Drugs and Rare indications in the US and in EU.
Senior scientific analyst – chemistry, biochemistry and neuroscience. R&D consulting, due diligence, business intelligence, IP, value boosters.
15 years experience M&A, corporate finance, healthcare and medtech, supply chain.
Over 25 years’ experience in new product launches and global commercialization infrastructure, publicly traded and private organizations. Ophthalmology focus.